Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECIDE: Docetaxel and Cisplatin Induction in Head and Neck Cancer
NCT02061631Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Sanofi. Primary endpoint: Overall Response Rate (Complete Response + Partial Response) after Induction. Started May 2014; status: completed.
02
Drugs
docetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02061631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061631.